DUBLIN – Another big gun has entered the oncolytic virus fray. Prompted by positive progress in its collaboration with Viratherapeutics GmbH, Boehringer Ingelheim GmbH has exercised an option to buy the company outright in a deal worth €210 million (US$245 million) in total.